United States

Developed Europe

Developed Rest of World

Emerging Markets

Total Internetional

Revenue by Geography

Revenue segments as reported by the company.

Primary Care

Specialty Care

Oncology

Pfizer CentreOne

Vaccines

Hospital

Internal Medicine

Rare Disease

Inflammation & Immunology

Pfizer Ignite

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, informational and administrative expenses

Research and development expenses

Amortization of intangible assets

Restructuring charges and certain acquisition-related costs

Other (income)/deductions

Acquired in-process research and development expenses

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Pfizer

Sildenafil is a medication used to treat erectile dysfunction and pulmonary arterial hypertension. It is sold as the brand name Viagra among others.

Viagra

Atorvastatin is a member of the medication class known as statins, which are used primarily as a lipid-lowering agent and for prevention of events associated with cardiovascular disease. Like all statins, atorvastatin works by inhibiting HMG-CoA reductase, an enzyme found in liver tissue that plays a key role in production of cholesterol in the body. It is marketed under the trade name Lipitor among others

Lipitor

Pfizer Inc. is a research-based global biopharmaceutical company, which engages in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products worldwide. The firm works across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases. The company was founded by Charles Pfizer Sr. and Charles Erhart in 1849 and is headquartered in New York, NY.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Pfizer exceeds $100B in revenue, eyes growth amid challenges

Pfizer's exceptional 2022 performance sets the stage for continued success in 2023.
Strategic investments in R&D and new product launches drive revenue growth expectations.
Challenges include transitioning from emergency status and revenue decline from COVID-related products.
Opportunities lie in increased adoption of combo vaccines and business development goals.

Pfizer reports solid Q1 results, eyes growth through innovation

Pfizer's Q1 performance was strong, driven by revenue growth and patient reach.
The company faces challenges in COVID franchise transition and stock performance.
Strategic acquisitions, new product launches, and market monitoring offer growth opportunities.
Pfizer's focus on innovation, trustworthiness, and commercial efficiency underpin its future success.

Pfizer reports Q2 growth amidst COVID uncertainties and therapeutic optimism

Pfizer's Q2 performance reflects growth in non-COVID revenues, strategic acquisitions, and a focus on new product launches. Challenges include uncertainties in revenue forecasts and operational adjustments post-acquisitions. Opportunities lie in therapeutic advancements and the potential of mRNA flu vaccines.

Pfizer reports strong Q3 performance, eyes growth in non-COVID products

Pfizer's Q3 performance showcased resilience in non-COVID product revenue growth, offsetting COVID-related declines. The company's strategic focus on global health impact and innovative acquisitions positions it for future growth. Challenges in the COVID product segment persist, but Pfizer remains optimistic about opportunities in new product launches and cancer treatment advancements.

Pfizer reports solid 2023 performance, eyes growth and cost savings

Pfizer's 2023 performance was strong despite challenges, with a focus on oncology, R&D, and cost savings. The company aims for revenue growth in 2024, emphasizing shareholder value and strategic priorities.

Pfizer reports robust Q1 earnings, eyes international growth and pipeline

Pfizer's Q1 2024 performance showcased strong revenue figures and strategic focus on non-COVID products and oncology, underlining the company's resilience and growth potential.
While facing challenges in adult market contraction and gross margin issues, Pfizer's strengths in pipeline innovation, product performance, and international market growth position it well for the future.
The company's opportunities lie in continued international expansion, consumer engagement initiatives, and upcoming pipeline advancements, signaling a path for sustained growth and innovation.

Pfizer reports strong Q2 earnings, raises guidance amid leadership changes

Pfizer's Q2 2024 earnings call reflects a robust performance, marked by revenue growth, leadership changes, and enhanced guidance. The company's strategic focus on oncology, vaccines, and product differentiation positions it for continued success. Challenges include maintaining market share post-generics and managing growth expectations for VYNDAQEL.

Pfizer reports robust Q3 earnings, eyes international market growth

Pfizer's Q3 earnings call highlighted strong performance, pipeline advancements, and a focus on shareholder value creation. Challenges include addressing the impact of IRA and maintaining growth in specific product lines. Opportunities lie in international market expansion and continued pipeline innovation.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Apple

Amazon

Chevron

Freeport-McMoRan

JPMorgan Chase & Co

Lockheed Martin

Microsoft

Tesla

Walmart

These blue-chip stocks to buy for 2022 offer upside potential in addition to strong cash flows that provide dividend visibility. The post 10 Best Blue-Chip Stocks to Buy for Growth and Dividends in 2022 appeared first on InvestorPlace.

10 Best Blue-Chip Stocks to Buy for Growth and Dividends in 2022

AbbVie

Abbott Labs

Home Depot

Dividend stocks could be worth paying attention to as the Federal Reserve may look to pull back its monetary support.

Best Stocks To Buy Today? 4 Dividend Stocks To Check Out

Is (PFE) Outperforming Other Medical Stocks This Year?

Is Pfizer (PFE) Stock Outpacing Its Medical Peers This Year?

Automatic Data Processing

BioNTech SE

Better-Than-Expected Private Payrolls in October.

Better-Than-Expected Private Payrolls in October

Shortly after the U.S. FDA authorised Pfizer Inc's (NYSE: PFE) COVID-19 vaccine for children as young as five years old, the CDC has followed in its footsteps, removing the final regulatory hurdle in the path to getting kids vaccinated. Pfizer's vaccine is over 90% effective in children Children will be given a lower dose; 10 […] The post CDC approves Pfizer's COVID-19 vaccine for children appeared first on Invezz.

CDC approves Pfizer's COVID-19 vaccine for children

Pharmaceutical concern  Pfizer Inc. (NYSE:PFE ) is struggling for direction this morning, last seen up 0.1% at $45.52, after the U.S. Centers for Disease Control and Prevention (CDC) recommended the use of its Covid-19 vaccine on children ages 5 to 11.

Options Bulls Blast Pfizer Stock on CDC Endorsement

Pfizer Inc. (PFE) CEO Albert Bourla on Q3 2021 Results - Earnings Call Transcript

Children as young as five will be offered coronavirus vaccines in the US, after health officials gave the final sign-off to Pfizer's jab.

US approves Pfizer COVID vaccine for children as young as five

Vaccinations for young children could start this week.

CDC Director Recommends Pfizer Vaccine For Kids Ages 5 To 11

Setbacks have resulted in delays across all three of Pfizer Inc's (NYSE: PFE) gene therapy programs, the Company revealed in its Q3 conference call. Pfizer slammed breaks on its Sangamo-partnered Phase 3 hemophilia A study after some patients reported high Factor VIII levels, an essential blood-clotting protein.

Pfizer Unveils Delays Across Its Gene Therapy Programs

An advisory committee to the Centers for Disease Control and Prevention unanimously endorsed the coronavirus vaccine for children ages 5 to 11.

CDC panel recommends Pfizer's COVID vaccine for kids 5 to 11

CDC Committee Recommends Pfizer Vaccine For Kids Ages 5 To 11

Children ages 5 to 11 will be able to get a Covid-19 vaccine after the CDC cleared Pfizer's doses for younger kids Tuesday night, allowing many parents across the U.S. to breathe a sigh of relief.

CDC panel unanimously recommends Pfizer Covid vaccine for kids ages 5 to 11 in critical step toward clearance

The CEO of Pfizer said the U.S. will have enough supply of vaccines for all kids as a CDC panel meets to decide whether or not to approve the shots.

Pfizer will have enough Covid vaccine doses available for every U.S. kid following clearance, CEO says

An influential advisory panel voted Tuesday that all children ages 5 to 11 should get Pfizer's pediatric COVID-19 shots, putting the U.S. on the brink of a major expansion of vaccinations — and a final decision is expected within hours.

CDC panel recommends Pfizer's COVID-19 vaccine for kids ages 5 to 11

Pfizer is getting ready to start shipping children's vaccines, and PFE stock is rising. That's not the only good news for investors, though.

PFE Stock Alert: 3 Catalysts Giving Pfizer Stock a Shot in the Arm Today

In case you were wondering how COVID-19 vaccine sales would affect third-quarter earnings for Pfizer Inc. (NYSE: PFE), you got the answer on Tuesday before the open. The vaccine was a huge boost to third-quarter earnings and revenue, and it instigated higher FY2021 guidance.

PreMarket Prep Stock Of The Day: Pfizer

The stock price of Pfizer Inc. (NYSE: PFE) increased by over 4% during intraday trading today. This is why it happened.

PFE Stock: Why The Price Increased Today

Pfizer is hiking sales expectations for its top-selling COVID-19 vaccine again, and its early look at 2022 also falls well above Wall Street forecasts. The drugmaker said Tuesday that it now expects to book about $36 billion in revenue from vaccine Comirnaty this year.

Pfizer surpasses Q3 forecasts as COVID vaccine sales soar

An advisory committee to the Centers for Disease Control and Prevention is meeting now to discuss whether to recommend the COVID vaccine for younger kids.

CDC panel votes today on Pfizer's COVID vaccine for kids 5 to 11

Pfizer (PFE) beats third-quarter estimates for earnings and sales, and lifts guidance for 2021.

Pfizer (PFE) Q3 Earnings Top, COVID Vaccine Drives 2021 View Up

Fed Set to Start Vital FOMC Meeting

Bank of America

New Pacific Metals Corp

Safe-T Group Ltd - ADR

12.05 pm: S&P 500 hits a record as run of strong corporate earnings continues US stocks were higher in noon trading, boosted by corporate earnings ahead of the Federal Reserve's policy decision tomorrow afternoon. At midday, the Dow rose 91 points to 36,005, while the S&P 500 added 13 points at 4,627 and the tech-heavy Nasdaq gained 27 points to 15,623.

News for Pfizer Stock (PFE)